Project description:<p>Plasmacytoid dendritic cells (pDC) are a subset of dendritic cells with unique immunophenotypic properties and functions. While their role in antiviral immunity through production of type I interferons is well-established, their contributions to anti-tumor immunity are less clear. While some evidence demonstrates that pDC in the tumor microenvironment (TME) may drive CD4+ T cell to become <a href="https://www.ncbi.nlm.nih.gov/gene/50943">Foxp3</a>+ T regulatory cells, little is understood about the relationship of pDC with cytotoxic CD8+ T cell, the key player in antitumor immune responses.</p> <p>In this study, we perform comprehensive immunophenotyping and functional analysis of pDC from the TME and draining lymph nodes of patients with head and neck squamous cell carcinoma (HNSCC) and identify a novel pDC subset characterized by expression of the TNF receptor superfamily member <a href="https://www.ncbi.nlm.nih.gov/gene/?term=7293">CD134 (OX40)</a>. We show that OX40 expression is expressed on intratumoral pDC in both humans and mice in a tumor-model specific fashion and that this subset of pDC enhances tumor associated-antigen (TAA)-specific CD8+ T cell responses. Through transcriptomic profiling of OX40-expressing pDC from the TME, we further characterize gene signatures unique to this pDC subset that support its role as an important immunostimulatory immune population in the TME.</p>
Project description:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive malignancy assumed to originate from plasmacytoid dendritic cells (pDCs), which mostly affects the skin, bone marrow and lymph nodes and sequentially other organ systems. We applied paired WES/RNA-seq combined with genome-wide copy-number analysis to characterize 47 BPDCN patients regarding mutational drivers, cytogenetic aberrations and gene-expression profiles.
Project description:Purpose: to explore the epigenomic landscape of innate immune cells stimulated with a novel adjuvant, 3M052 Methods: Mice were injected with 3M052. Draining lymph nodes were negatively selected for CD19+ and CD3+, then flow sorted into four populations: Dendritic cells (DCs), Double positive cells (DP, CD11b+BST1+), Ly6c+ cells (Ly6c), and plasmacytoid dendritic cells (pDCs). Lymph nodes were harvested at baseline (D0), 24 hours post-treatment (D1) or 28 days post-treatment (D28).
Project description:Purpose: To understand the innate immune response to an adjuvant, 3M052, and yellow fever vaccine, YFV Methods: Draining lymph nodes were negatively selected for CD19+ and CD3+, then flow sorted into four populations: Dendritic cells (DCs), Double positive cells (DP, CD11b+BST1+), Ly6c+ cells (Ly6c), and plasmacytoid dendritic cells (pDCs). Lymph nodes were harvested at baseline (D0), 24 hours post-treatment (D1) or 28 days post-treatment (D28). Results: TBD Conclusions: TBD
Project description:Gene expression profile in CD11c+ splenic dendritic cells and CD11c+CD103+ dendritic cells from mesenteric lymph nodes (MLN) of mice with DC-specific targeting of TGFBR2
